RZRumeng Zhang

Rumeng Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rumeng Zhang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Huan Wang

    Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

    1 shared publication
  • Keshuo Ding

    Department of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, China

    1 shared publication
  • Lin Ding

    Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China

    1 shared publication
  • Lin Dong

    Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China

    1 shared publication
  • Lin Li

    Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China

    1 shared publication
  • Linyan Zhu

    Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China

    1 shared publication

Latest Publications

  • Open Access

    CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma

    by Rumeng Zhang, Zhihao Wang, Huan Wang, Lin Li, Lin Dong, Lin Ding, Qiushuang Li, Linyan Zhu, Tiantian Zhang, Yong Zhu, et al.

    Colon cancer, thyroid cancer, and melanoma are common malignant tumors that seriously threaten human health globally. The B-Raf proto-oncogene, serine/threonine kinase (BRAF)(V600E) mutation is an important driver gene mutation in these cancer types. In this study, we identified that collagen triple helix repeat containing 1 (CTHRC1) expression was associated with the BRAF(V600E) mutation in colon cancer, thyroid cancer, and melanoma. Based on database analysis and clinical tissue studies, CTHRC1 was verified to correlate with poor prognosis and worse clinicopathological features in colon cancer and thyroid cancer patients, but not in patients with melanoma. Several signaling pathways, immune cell infiltration, and immunotherapy markers were associated with CTHRC1 expression. Additionally, a high level of CTHRC1 was correlated with decreased sensitivity to antitumor drugs (vemurafenib, PLX-4720, dabrafenib, and SB-590885) targeting the BRAF(V600E) mutation. This study provides evidence of a significant correlation between CTHRC1 and the BRAF(V600E) mutation, suggesting its potential utility as a diagnostic and prognostic biomarker in human colon cancer, thyroid cancer, and melanoma.